论文部分内容阅读
新生儿医学主要关注新生儿出生后功能调节失常导致的各种疾病,但现有的多数临床诊断技术在新生儿阶段的敏感性和特异性较差,仅能依靠形态学描述来评价疾病造成的器官损害。本文讨论蛋白质组学技术发现的临床生物标记,并着重探讨其在新生儿疾病中的应用。一、新生儿学领域亟待解决的临床问题在新生儿重症监护技术和治疗手段取得的重大进展中,分子诊断技术(蛋白质组学、基因组学和代谢组学等)发挥了积极作用。新兴的分子技术有望
Neonatal medicine focuses on various diseases caused by dysfunction of newborns after birth, but most existing clinical diagnostic techniques have poor sensitivity and specificity in neonatal stage and can only rely on morphological description to evaluate the disease Organ damage. This article discusses the clinical biomarkers discovered by proteomic techniques and focuses on its use in neonatal disease. First, the urgent need to solve clinical problems in neonatology Molecular monitoring techniques (proteomics, genomics and metabolomics, etc.) have played a positive role in the significant progress made in neonatal intensive care and treatment. Emerging molecular technology is expected